Business Context and Reporting Period
This Form 8-K, dated August 24, 2021, reports on a special meeting of stockholders held by Alpha Healthcare Acquisition Corp. (AHAC). The filing documents the approval of a business combination with Humacyte, Inc. Upon closing, AHAC will be renamed "Humacyte, Inc." and Humacyte, Inc. will become a wholly-owned subsidiary renamed "Humacyte Global, Inc."
Key Financial Metrics and Transaction Terms
The filing details the terms of the merger rather than standard operating financial metrics for a reporting period.
- Implied Equity Value: The transaction is based on an implied Humacyte vested equity value of $800,000,000.
- Share Issuance: Stockholders approved the issuance of up to 95,000,000 newly issued shares of New Humacyte Common Stock in the Business Combination.
- PIPE Investment: Stockholders approved the issuance of an aggregate of 17,500,000 shares of New Humacyte Common Stock in connection with the PIPE Investment.
- Capital Structure: The authorized shares of common stock will increase to 250,000,000 shares, and authorized "blank check" preferred stock will increase to 20,000,000 shares.
Note: The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for either entity.
Material Changes and Voting Results
On August 24, 2021, AHAC stockholders voted to approve eight proposals, all of which passed. The most significant material change is the corporate restructuring via the Business Combination.
- Business Combination Proposal: Approved with 7,862,833 votes for, 42,414 against, and 6,809 abstentions.
- Charter Amendment Proposal: Approved to restate the certificate of incorporation effective upon closing.
- Advisory Proposals: Stockholders approved eight non-binding advisory proposals regarding the name change, authorized share increases, director removal standards, perpetual existence, and removal of SPAC-specific provisions.
- Director Election: Eleven directors were elected to the board of New Humacyte, including Brady Dougan, Jeffrey H. Lawson, M.D., Ph.D., and Kathleen Sebelius.
- Compensation Plans: The Humacyte, Inc. 2021 Long-Term Incentive Plan and the 2021 Employee Stock Purchase Plan were approved.
Guidance, Outlook, and Risks
The filing confirms the successful shareholder vote required to proceed with the merger. The press release issued on August 24, 2021, is incorporated by reference as Exhibit 99.1. The filing does not contain specific forward-looking guidance, management commentary on future financial performance, or a detailed discussion of risks and contingencies beyond the standard transaction terms and the approval of the adjournment proposal if necessary to consummate the deal.
Key Facts for Investor Verification
- Verify the final closing date of the Business Combination and the effective time of the name change to "Humacyte, Inc."
- Confirm the final number of shares issued in the PIPE Investment and the total share count post-merger.
- Review the definitive proxy statement/prospectus filed on August 4, 2021, for detailed financial projections and risk factors not included in this 8-K.
- Monitor the transition of Humacyte, Inc. to "Humacyte Global, Inc." as a subsidiary and the integration of operations.
- Check for any subsequent filings regarding the actual cash proceeds received from the PIPE and the final capitalization table.